4.7 Review

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

期刊

BLOOD
卷 127, 期 20, 页码 2375-2390

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2016-01-643569

关键词

-

资金

  1. Italian Association for Cancer Research (AIRC, Milan) [10007]
  2. National Institutes of Health (NIH)/National Cancer Institute (NCI) Cancer Center [P30 CA008748]
  3. American Society of Hematology
  4. Josep Carreras Foundation
  5. Fondazione Italiana Linfomi (FIL)
  6. Leukemia Clinical Research Foundation
  7. University of Chicago Comprehensive Cancer Center
  8. Beckman Coulter Corporation
  9. Celgene Corporation
  10. Dako
  11. Genentech Corporation
  12. Incyte Corporation
  13. Leica Corporation
  14. Millennium Pharmaceuticals
  15. Pharmacyclics
  16. Seattle Genetics Corporation
  17. Sysmex Corporation
  18. Ventana Medical Systems, Inc of the Roche Group

向作者/读者索取更多资源

A revision of the nearly 8-year-old World Health Organization classification of the lymphoid neoplasms and the accompanying monograph is being published. It reflects a consensus among hematopathologists, geneticists, and clinicians regarding both updates to current entities as well as the addition of a limited number of new provisional entities. The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies. The major changes are reviewed with an emphasis on the most important advances in our understanding that impact our diagnostic approach, clinical expectations, and therapeutic strategies for the lymphoid neoplasms.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据